ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Chidamide Plus Exemestane for Postmenopausal Patients with Hormone-Receptor-Positive Advanced Breast Cancer (ACE Study): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial
SSRN Electronic Journal
◽
10.2139/ssrn.3327363
◽
2019
◽
Author(s):
Zefei Jiang
◽
Wei Li
◽
Xichun Hu
◽
Qingyuan Zhang
◽
Tao Sun
◽
...
Keyword(s):
Breast Cancer
◽
Advanced Breast Cancer
◽
Hormone Receptor
◽
Advanced Breast
◽
Phase 3
◽
Double Blind
◽
Double Blind Placebo
◽
Hormone Receptor Positive
◽
Ace Study
Download Full-text
Related Documents
Cited By
References
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology
◽
10.1016/s1470-2045(17)30688-5
◽
2018
◽
Vol 19
(1)
◽
pp. 87-100
◽
Cited By ~ 151
Author(s):
Angelo Di Leo
◽
Stephen Johnston
◽
Keun Seok Lee
◽
Eva Ciruelos
◽
Per E Lønning
◽
...
Keyword(s):
Breast Cancer
◽
Advanced Breast Cancer
◽
Postmenopausal Women
◽
Hormone Receptor
◽
Advanced Breast
◽
Phase 3
◽
Double Blind
◽
Mtor Inhibition
◽
Double Blind Placebo
◽
Hormone Receptor Positive
Download Full-text
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology
◽
10.1016/s1470-2045(17)30376-5
◽
2017
◽
Vol 18
(7)
◽
pp. 904-916
◽
Cited By ~ 248
Author(s):
José Baselga
◽
Seock-Ah Im
◽
Hiroji Iwata
◽
Javier Cortés
◽
Michele De Laurentiis
◽
...
Keyword(s):
Breast Cancer
◽
Advanced Breast Cancer
◽
Hormone Receptor
◽
Advanced Breast
◽
Phase 3
◽
Double Blind
◽
Double Blind Placebo
◽
Postmenopausal Hormone
◽
Hormone Receptor Positive
Download Full-text
Faculty Opinions recommendation of Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.732279400.793559076
◽
2019
◽
Author(s):
Ahmad Awada
Keyword(s):
Breast Cancer
◽
Advanced Breast Cancer
◽
Postmenopausal Women
◽
Hormone Receptor
◽
Advanced Breast
◽
Phase 3
◽
Double Blind
◽
Mtor Inhibition
◽
Double Blind Placebo
◽
Hormone Receptor Positive
Download Full-text
Faculty Opinions recommendation of Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.727683217.793533460
◽
2017
◽
Author(s):
Aleix Prat
Keyword(s):
Breast Cancer
◽
Advanced Breast Cancer
◽
Hormone Receptor
◽
Advanced Breast
◽
Phase 3
◽
Double Blind
◽
Double Blind Placebo
◽
Postmenopausal Hormone
◽
Hormone Receptor Positive
Download Full-text
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
The Lancet
◽
10.1016/s0140-6736(16)32389-3
◽
2016
◽
Vol 388
(10063)
◽
pp. 2997-3005
◽
Cited By ~ 212
Author(s):
John F R Robertson
◽
Igor M Bondarenko
◽
Ekaterina Trishkina
◽
Mikhail Dvorkin
◽
Lawrence Panasci
◽
...
Keyword(s):
Breast Cancer
◽
Advanced Breast Cancer
◽
Hormone Receptor
◽
Advanced Breast
◽
Phase 3
◽
Double Blind
◽
Hormone Receptor Positive
Download Full-text
Faculty Opinions recommendation of Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.718355395.793494247
◽
2014
◽
Author(s):
Ana Maria Gonzalez-Angulo
Keyword(s):
Breast Cancer
◽
Advanced Breast Cancer
◽
Advanced Breast
◽
Her2 Positive
◽
Phase 3
◽
Double Blind
◽
Double Blind Placebo
Download Full-text
A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)
European Journal of Cancer
◽
10.1016/j.ejca.2015.10.012
◽
2016
◽
Vol 53
◽
pp. 144-154
◽
Cited By ~ 19
Author(s):
Konstantinos Tryfonidis
◽
Gul Basaran
◽
Jan Bogaerts
◽
Marc Debled
◽
Luc Dirix
◽
...
Keyword(s):
Breast Cancer
◽
Advanced Breast Cancer
◽
Phase Ii
◽
Hormone Receptor
◽
Phase Ii Trial
◽
Double Blind
◽
Double Blind Placebo
◽
Multicentre Phase
◽
European Organisation
◽
Hormone Receptor Positive
Download Full-text
Abstract OT3-2-10: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of fulvestrant with or without PD-0332991 (palbociclib) ± goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) whose disease progressed after prior endocrine therapy
10.1158/0008-5472.sabcs13-ot3-2-10
◽
2013
◽
Cited By ~ 2
Author(s):
N Turner
◽
F André
◽
S Loibl
◽
J Ro
◽
H Iwata
◽
...
Keyword(s):
Breast Cancer
◽
Metastatic Breast Cancer
◽
Endocrine Therapy
◽
Hormone Receptor
◽
Controlled Trial
◽
Metastatic Breast
◽
Phase 3
◽
Double Blind
◽
Double Blind Placebo
◽
Hormone Receptor Positive
Download Full-text
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
The Lancet Oncology
◽
10.1016/s1470-2045(14)70138-x
◽
2014
◽
Vol 15
(6)
◽
pp. 580-591
◽
Cited By ~ 281
Author(s):
Fabrice André
◽
Ruth O'Regan
◽
Mustafa Ozguroglu
◽
Masakazu Toi
◽
Binghe Xu
◽
...
Keyword(s):
Breast Cancer
◽
Advanced Breast Cancer
◽
Advanced Breast
◽
Her2 Positive
◽
Phase 3
◽
Double Blind
◽
Double Blind Placebo
Download Full-text
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
The Lancet Oncology
◽
10.1016/s1470-2045(18)30292-4
◽
2018
◽
Vol 19
(7)
◽
pp. 904-915
◽
Cited By ~ 196
Author(s):
Debu Tripathy
◽
Seock-Ah Im
◽
Marco Colleoni
◽
Fabio Franke
◽
Aditya Bardia
◽
...
Keyword(s):
Breast Cancer
◽
Advanced Breast Cancer
◽
Endocrine Therapy
◽
Hormone Receptor
◽
Premenopausal Women
◽
Advanced Breast
◽
Phase 3
◽
Hormone Receptor Positive
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close